Open AccessOptimization of the Dosage of Flucytosine in Combination with Amphotericin B for Disseminated Candidiasis: a Pharmacodynamic Rationale for Reduced Dosing
Author(s) -
William Hope,
Peter Warn,
Andrew Sharp,
Paul Reed,
Brian Keevil,
Arnold Louie,
Thomas J. Walsh,
David W. Denning,
George L. Drusano
Publication year - 2007
Publication title -
antimicrobial agents and chemotherapy
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.07
H-Index - 259
eISSN - 1070-6283
pISSN - 0066-4804
DOI - 10.1128/aac.00488-07
Subject(s) - flucytosine , amphotericin b , pharmacodynamics , pharmacology , dosing , pharmacokinetics , medicine , antifungal , dermatology
Amphotericin B and flucytosine (5FC) have an additive effect when used for disseminated candidiasis. Here, we bridge the results of an experimental pharmacodynamic study to humans and demonstrate that a 5FC dosage of 25 mg/kg of body weight/day in four divided doses in combination with amphotericin B produces near-maximal effect.